These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 2704582)

  • 1. Immunoreactive trypsinogen screening for cystic fibrosis: characterization of infants with a false-positive screening test.
    Rock MJ; Mischler EH; Farrell PM; Bruns WT; Hassemer DJ; Laessig RH
    Pediatr Pulmonol; 1989; 6(1):42-8. PubMed ID: 2704582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods.
    Gregg RG; Simantel A; Farrell PM; Koscik R; Kosorok MR; Laxova A; Laessig R; Hoffman G; Hassemer D; Mischler EH; Splaingard M
    Pediatrics; 1997 Jun; 99(6):819-24. PubMed ID: 9164776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
    Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
    J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels.
    Rock MJ; Mischler EH; Farrell PM; Wei LJ; Bruns WT; Hassemer DJ; Laessig RH
    Pediatrics; 1990 Jun; 85(6):1001-7. PubMed ID: 2187173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
    Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
    Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols.
    Gregg RG; Wilfond BS; Farrell PM; Laxova A; Hassemer D; Mischler EH
    Am J Hum Genet; 1993 Mar; 52(3):616-26. PubMed ID: 7680526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of 47,213 infants in neonatal screening for cystic fibrosis, using pancreatitis-associated protein and immunoreactive trypsinogen assays].
    Barthellemy S; Maurin N; Roussey M; Férec C; Murolo S; Berthézène P; Iovanna JL; Dagorn JC; Sarles J
    Arch Pediatr; 2001 Mar; 8(3):275-81. PubMed ID: 11270251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
    Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
    J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystic fibrosis newborn screening: the importance of bloodspot sample quality.
    Doull I; Course CW; Hanks RE; Southern KW; Forton JT; Thia LP; Moat SJ
    Arch Dis Child; 2021 Mar; 106(3):253-257. PubMed ID: 32859613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
    Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R
    J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.
    Massie J; Curnow L; Tzanakos N; Francis I; Robertson CF
    Arch Dis Child; 2006 Mar; 91(3):222-5. PubMed ID: 16243854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of specificity and sensitivity of IRT/IRT protocol in the cystic fibrosis newborn screening program: 6-year experience of three tertiary centers.
    Ramasli Gursoy T; Asfuroglu P; Sismanlar Eyuboglu T; Aslan AT; Yilmaz AI; Unal G; Kibar BS; Pekcan S; Hangul M; Kose M; Budakoglu II; Acican D
    Eur J Pediatr; 2023 Mar; 182(3):1067-1076. PubMed ID: 36565324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for cystic fibrosis in New York State: considerations for algorithm improvements.
    Kay DM; Maloney B; Hamel R; Pearce M; DeMartino L; McMahon R; McGrath E; Krein L; Vogel B; Saavedra-Matiz CA; Caggana M; Tavakoli NP
    Eur J Pediatr; 2016 Feb; 175(2):181-93. PubMed ID: 26293390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population.
    Sommerburg O; Lindner M; Muckenthaler M; Kohlmueller D; Leible S; Feneberg R; Kulozik AE; Mall MA; Hoffmann GF
    J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S263-71. PubMed ID: 20714932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoreactive trypsinogen levels in newborn screened infants with an inconclusive diagnosis of cystic fibrosis.
    Ooi CY; Sutherland R; Castellani C; Keenan K; Boland M; Reisman J; Bjornson C; Chilvers MA; van Wylick R; Kent S; Price A; Mateos-Corral D; Hughes D; Solomon M; Zuberbuhler P; Brusky J; Durie PR; Ratjen F; Gonska T
    BMC Pediatr; 2019 Oct; 19(1):369. PubMed ID: 31640630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening.
    Sontag MK; Corey M; Hokanson JE; Marshall JA; Sommer SS; Zerbe GO; Accurso FJ
    J Pediatr; 2006 Nov; 149(5):650-657. PubMed ID: 17095337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany.
    Sommerburg O; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Stopsack M; Gahr M; Hoffmann GF; Mall MA
    Pediatr Pulmonol; 2015 Jul; 50(7):655-64. PubMed ID: 25914230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.
    Rock MJ; Hoffman G; Laessig RH; Kopish GJ; Litsheim TJ; Farrell PM
    J Pediatr; 2005 Sep; 147(3 Suppl):S73-7. PubMed ID: 16202788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations.
    Hammond KB; Abman SH; Sokol RJ; Accurso FJ
    N Engl J Med; 1991 Sep; 325(11):769-74. PubMed ID: 1870650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A survey of newborn screening for cystic fibrosis in Europe.
    Southern KW; Munck A; Pollitt R; Travert G; Zanolla L; Dankert-Roelse J; Castellani C;
    J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.